Stock Analysis, Dividends, Split History

EGY / VAALCO Energy, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)160.83
Enterprise Value ($M)94.45
Book Value ($M)20.48
Book Value / Share0.34
Price / Book6.41
NCAV ($M)-20.35
NCAV / Share-0.34
Price / NCAV-6.63
Share Statistics
Common Stock Shares Outstanding 58,862,876
Common Shares Outstanding 58,862,876
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.50
Return on Assets (ROA)0.12
Return on Equity (ROE)-26.96
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.02
Income Statement (mra) ($M)
Oil And Gas Sales Revenue77,025,000.00
Operating Income19.95
Net Income9.65
Earnings Per Share Basic0.16
Earnings Per Share Diluted0.16
Cash Flow Statement (mra) ($M)
Cash From Operations6.66
Cash from Investing-1.65
Cash from Financing-1.65
Identifiers and Descriptors
Central Index Key (CIK)894627
Related CUSIPS
91851C901 91851C951

Split History

Stock splits are used by VAALCO Energy, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

VAALCO Energy, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-07 seekingalpha
The following slide deck was published by VAALCO Energy, Inc. in conjunction with their 2018 Q2 earnings call. (3-0)

[Opinion] An African Perspective: No Good Will Come From NOPEC

2018-07-24 oilvoice
Opinion: NJ Ayuk, CEO of Centurion Law Group --Throughout the years I spent as an undergraduate and law school student in the U.S., one of the things I truly admired was American ingenuity. I loved following news stories about U.S. startups that scraped together enough money to go overseas, explored for oil – and despite overwhelming odds, achieved success. (15-0)

Vaalco Energy Regains NYSE Full Compliance

2018-06-06 seekingalpha
VAALCO announced that the workover operations on the S. Tchibala 1HB well had been completed successfully and workover operations are ongoing for the Avouma 2H well. (1-1)

3 of the Best Penny Stocks To Buy Right Now

2018-05-16 investorplace
Penny stocks get a bad rap — and it’s somewhat well-deserved. While a price below $5 might make a stock seem “cheap,” that’s actually not the case. An investor’s ownership of a company on a percentage basis, and the valuation of that company, is what matters. Whether a stock is priced at $4, $0.40, or $400 doesn’t in and of itself affect the potential gains — or losses — in that stock. The best penny stocks to buy shouldn’t be buys because of their price — but rather their value. (58-3)

Vaalco Energy: Q1 Results Hit The Bull's Eye

2018-05-14 seekingalpha
VAALCO Energy indicated $30.66 million in revenues this 1Q'18 or 44.1% higher than a year ago and up a whopping 78.7% sequentially. (1-1)

CUSIP: 91851C201